Sanofi
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SNY research report →
About the company
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders.
- CEO
- Olivier Charmeil
- IPO
- 2002
- Employees
- 82,878
- HQ
- Paris, FR
Price Chart
- Market Cap
- $103.77B
- P/E
- 19.00
- P/S
- 1.92
- P/B
- 1.25
- EV/EBITDA
- 12.48
- Div Yield
- 5.43%
- Gross Margin
- 71.92%
- Op Margin
- 19.84%
- Net Margin
- 15.95%
- ROE
- 10.51%
- ROIC
- 7.50%
- Revenue
- $46.72B · 5.49%
- Net Income
- $7.81B · 40.52%
- EPS
- $3.20 · 45.79%
- Op Income
- $9.60B
- FCF YoY
- 72.34%
- 52W High
- $52.68
- 52W Low
- $40.89
- 50D MA
- $43.81
- 200D MA
- $46.92
- Beta
- 0.28
- Avg Volume
- 3.17M
Get TickerSpark's AI analysis on SNY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our SNY coverage
Recent articles, reports, and earnings notes.
Sanofi (SNY): Dupixent Drives a Buy Case
Sanofi is becoming a more focused biopharma compounder, led by Dupixent growth, vaccine strength, and expanding launch sales. The stock looks inexpensive versus its cash generation and earnings power.
Sanofi (SNY) drops 5% on downgrade and ex-dividend
Sanofi (SNY) drops about 5% after a Morgan Stanley downgrade and ex-dividend pressure, even as the drugmaker posted strong Q1 results. The selloff reflects investor concern over growth durability, pipeline depth, and reliance on Dupixent rather than a fresh operating setback.
Want a deeper read on SNY?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.